These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 20027193)

  • 41. Spectrum of renin angiotensin aldosterone system disorders in young hypertensives.
    Gilani M; Asif N; Akram A; Gilani M; Ijaz A; Malik SS
    J Pak Med Assoc; 2018 Aug; 68(8):1179-1182. PubMed ID: 30108382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aldosterone Stimulates Its Biosynthesis Via a Novel GPER-Mediated Mechanism.
    Caroccia B; Seccia TM; Piazza M; Prisco S; Zanin S; Iacobone M; Lenzini L; Pallafacchina G; Domening O; Poglitsch M; Rizzuto R; Rossi GP
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6316-6324. PubMed ID: 31125081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aldosterone Contributes to Sympathoexcitation in Renovascular Hypertension.
    Lincevicius GS; Shimoura CG; Nishi EE; Perry JC; Casarini DE; Gomes GN; Bergamaschi CT; Campos RR
    Am J Hypertens; 2015 Sep; 28(9):1083-90. PubMed ID: 25628418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Normoaldosteronemic aldosterone-producing adenoma: immunochemical characterization and diagnostic implications.
    Rossi GP; Gioco F; Fassina A; Gomez-Sanchez CE
    J Hypertens; 2015 Dec; 33(12):2546-9. PubMed ID: 26536091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new presentation of the chimeric CYP11B1/CYP11B2 gene with low prevalence of primary aldosteronism and atypical gene segregation pattern.
    Carvajal CA; Campino C; Martinez-Aguayo A; Tichauer JE; Bancalari R; Valdivia C; Trejo P; Aglony M; Baudrand R; Lagos CF; Mellado C; Garcia H; Fardella CE
    Hypertension; 2012 Jan; 59(1):85-91. PubMed ID: 22083159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary hyperaldosteronism due to adrenal microadenoma: a curable cause of refractory hypertension.
    Myint KS; Watts M; Appleton DS; Lomas DJ; Jamieson N; Taylor KP; Coghill S; Brown MJ
    J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):103-6. PubMed ID: 18584586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deficiency of T-type Ca
    Thuesen AD; Finsen SH; Rasmussen LL; Andersen DC; Jensen BL; Hansen PBL
    Am J Physiol Renal Physiol; 2019 Aug; 317(2):F254-F263. PubMed ID: 31042060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A case of primary aldosteronism with a negative aldosterone-to-renin ratio.
    Liu F; Wang L; Ding Y
    BMC Cardiovasc Disord; 2021 Jul; 21(1):350. PubMed ID: 34294029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple gene approaches to delineate the role of the renin-angiotensin-aldosterone system in nephropathy.
    Michel MC; Hahntow I; Koopmans RP
    J Hypertens; 2005 Feb; 23(2):269-72. PubMed ID: 15662212
    [No Abstract]   [Full Text] [Related]  

  • 51. Investigating mineralocorticoid hypertension.
    Nussberger J
    J Hypertens Suppl; 2003 May; 21(2):S25-30. PubMed ID: 12929904
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Hypertension and mineralocorticoids. Usefulness of renin and aldosterone measurements].
    Fardella CE; Montero J; Mosso L
    Rev Med Chil; 1999 May; 127(5):604-10. PubMed ID: 10451632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Primary aldosteronism].
    Fardella CE; Mosso LM; Carvajal CA
    Rev Med Chil; 2008 Jul; 136(7):905-14. PubMed ID: 18949169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
    Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
    Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of aldosterone and MR blockade on the brain and the kidney.
    Stier CT; Rocha R; Chander PN
    Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension.
    Ardhanari S; Kannuswamy R; Chaudhary K; Lockette W; Whaley-Connell A
    Adv Chronic Kidney Dis; 2015 May; 22(3):185-95. PubMed ID: 25908467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
    Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
    J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A case of monozygotic twins with primary aldosteronism: a case report.
    Yoshida T; Uchiwa Y; Sugimachi K; Naruse M
    J Hum Hypertens; 2017 Jun; 31(6):422-423. PubMed ID: 28150818
    [No Abstract]   [Full Text] [Related]  

  • 60. Overview of aldosterone-related genetic syndromes and recent advances.
    Zennaro MC; Fernandes-Rosa FL; Boulkroun S
    Curr Opin Endocrinol Diabetes Obes; 2018 Jun; 25(3):147-154. PubMed ID: 29432258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.